Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease

Doonan, James and Thomas, David and Wong, Michelle H. and Ramage, Hazel J. and Al-Riyami, Lamyaa and Lumb, Felicity E. and Bell, Kara S. and Fairlie-Clarke, Karen J. and Suckling, Colin J. and Michelsen, Kathrin S. and Jiang, Hui-Rong and Cooke, Anne and Harnett, Margaret M. and Harnett, William (2018) Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 23 (10). 2669. ISSN 1420-3049

[img]
Preview
Text (Doonan-etal-Molecules-2018-Failure-of-the-anti-inflammatory-parasitic-worm-product-ES-62-to-provide-protection)
Doonan_etal_Molecules_2018_Failure_of_the_anti_inflammatory_parasitic_worm_product_ES_62_to_provide_protection.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (3MB)| Preview

    Abstract

    Parasitic helminths and their isolated secreted products show promise as novel treatments for allergic and autoimmune conditions in humans. Foremost amongst the secreted products is ES-62, a glycoprotein derived from Acanthocheilonema viteae, a filarial nematode parasite of gerbils, which is anti-inflammatory by virtue of covalently-attached phosphorylcholine (PC) moieties. ES-62 has been found to protect against disease in mouse models of rheumatoid arthritis, systemic lupus erythematosus, and airway hyper-responsiveness. Furthermore, novel PC-based synthetic small molecule analogues (SMAs) of ES-62 have recently been demonstrated to show similar anti-inflammatory properties to the parent molecule. In spite of these successes, we now show that ES-62 and its SMAs are unable to provide protection in mouse models of certain autoimmune conditions where other helminth species or their secreted products can prevent disease development, namely type I diabetes, multiple sclerosis and inflammatory bowel disease. We speculate on the reasons underlying ES-62’s failures in these conditions and how the negative data generated may help us to further understand ES-62’s mechanism of action.